Integra Lifesciences Holdings (IART) Cash from Financing Activities (2009 - 2026)

Integra Lifesciences Holdings' Cash from Financing Activities history runs 18 years deep, the most recent figure standing at $8.3 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 76.55% year-over-year to $8.3 million; the TTM figure through Mar 2026 stood at $1.3 million (up 101.47% YoY), while the FY2025 annual figure was $28.3 million, down 88.09% from the prior year.
• Cash from Financing Activities came in at $8.3 million for Q1 2026 at Integra Lifesciences Holdings, down from $24.3 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $358.7 million in Q1 2024 to a low of -$162.7 million in Q1 2023.
• A 5-year average of -$12.2 million and a median of -$10.7 million in 2023 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities sank 18852.21% in 2022 and surged 440.45% in 2025, its largest moves.
• Integra Lifesciences Holdings' Cash from Financing Activities stood at -$97.7 million in 2022, then soared by 92.95% to -$6.9 million in 2023, then fell by 3.77% to -$7.2 million in 2024, then soared by 440.45% to $24.3 million in 2025, then tumbled by 65.91% to $8.3 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $8.3 million, $24.3 million, and -$10.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison